Navigation Links
Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
Date:8/12/2008

Locoid Lotion was recently introduced at the Summer American Academy of Dermatology Meeting, in Chicago, Illinois, for the treatment of mild-to-moderate atopic dermatitis in pediatric to adult patients. Triax Pharmaceuticals, LLC, the marketers of Locoid Lipocream (hydrocortisone butyrate 0.1%) a leading mid-potency brand in corticosteroids, recently launched the new product to cover larger and hairy affected areas with an elegant, non-greasy application to treat atopic dermatitis.

Crawford, NJ (PRWEB) August 12, 2008 -- A new product to treat http://www.locoid.com/ [atopic dermatitis] in adult to http://www.locoid.com/ [pediatric] patients as young as three months of age was recently introduced. Locoid Lotion, launched by http://www.triaxpharma.com/ [Triax Pharmaceuticals, LLC] - the marketers of the leading mid-potency corticosteroid brand Locoid Lipocream (hydrocortisone butyrate 0.1%) - is a new lotion vehicle especially designed to cover larger and hairy affected areas with an elegant, non-greasy application to treat milt to moderate atopic dermatitis. 1.

http://www.locoid.com/ [Atopic dermatitis] (AD) is very common in the United States. It affects nearly 15 million people (1% to 3% of adults and 10% to 20% of children).1, and accounts for 10 to 20 percent of all visits to dermatologists. The key symptom is pruritus (itching), leading to the description of AD as "the itch that rashes." Itching is fairly constant during daytime hours and worsens at night, causing sleep disturbances and discomfort. For parents of children with AD, it is the number one reason for days of missed work in the United States and it is a common cause of workplace disability for all adults. People who live in cities and in drier climates appear more likely to develop http://www.locoid.com/ [atopic dermatitis].2.

http://www.locoid.com/ [Locoid Lotion] and Locoid Lipocream have been formulated with high concentration of barrier-enhancing lipids. This unique feature provides skin barrier restorative properties for a wide range of patients.

Locoid® Lotion is the ONLY class 5 corticosteroid indicated for pediatric patients 3 months of age and older. It has been proven to provide significant relief of all AD symptoms in pediatric and adult patients. In 89% of patients, symptoms of skin-barrier disruption were eliminated or reduced to mild. By Day 8, average pruritis-symptom scores were reduced to less than mild2.

Topical Corticosteroids are widely used in the treatment of mild to moderate inflammatory skin diseases. Locoid® Lotion has a wide range of benefits which include the following:

  • Easy to apply and rapidly absorbed, which in turn, makes it easy to spread over affected areas, including large and hairy areas. The cosmetic acceptability promotes patient compliance3.
  • Promotes hydration and enhances penetration of the active drug.
  • Non-halogenated, which allows for low risk of potential side effects.
  • Unlike the majority of topical corticosteroids, Locoid® Lotion contains no irritants such as propylene glycol, lanolin, or imidurea and is formulated in a non-irritating and fragrance-free base.

Dr. Adelaide Hebert, a dermatologist based in Houston, Texas remarks, "Locoid Lotion has unique properties, and is an ideal product for certain hard to treat areas such as the chest, the arms, and the legs."

Locoid® Lotion is available by prescription through pharmacies nationwide in a 2 fl. oz. bottle (4 fl. oz. to follow soon).

Reversible HPA axis suppression may occur with the potential for corticosteroid insufficiency. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if a concomitant skin infection develops. Discontinue use if irritation develops.

About Triax Pharmaceuticals, LLC
Triax Pharmaceuticals is a specialty pharmaceutical company with integrated sales, marketing, and development expertise that markets a portfolio of branded dermatological products. Triax focuses on marketing dermatology products in the United States. Triax sales force is comprised of dermatology sales professionals nationwide. Triax Pharmaceuticals, LLC recently launched its fourth product, Locoid® Lotion .

In addition to industry leader Locoid Lipocream and new Locoid® Lotion, Triax Pharmaceuticals also markets two products in the acne category:

http://www.tretinx.com/ [Tretin-X® (tretinoin)] Kit is available in 0.025% cream, 0.05% cream, 0.1% cream, 0.01% gel, and 0.025% gel. Each kit contains Tretinoin cream or gel along with two cosmetic products included at no additional cost to the patient: T3™ Foaming Cleanser and T3 Soothing Moisturizer.

http://www.minocinpac.com [Minocin® (minocycline HCl) Pellet-filled Capsules Professional Acne Care (P.A.C.)]. The MINOCIN PAC system contains a 60 count bottle of Minocin Pellet-Filled Capsules (50 mg or 100 mg) and three skincare products (at no additional cost to the patient).

1Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008; 7:266-271.
2 http://www.niams.nih.gov/Health_Info/Atopic_Dermatitis/default.asp#link_b
3 Fowler JF Jr. Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis. Cutis 2005; 75:125-131.

For more information on Locoid® Lotion for adult to pediatric patients with atopic dermatitis, please contact Peter Volk or Aleen Hosdaghian of Triax Pharmaceuticals, LLC, 908.372.0500.
See www.locoid.com for full prescribing information.

# # #

Read the full story at http://www.prweb.com/releases/2008/08/prweb1190714.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid  Lotion 0.1% 
(Date:8/21/2017)... ... August 21, 2017 , ... ... it has become the Official Technology Partner of North Country Region Volleyball and ... Event Systems) volleyball software, along with providing sport management software to their member ...
(Date:8/21/2017)... York, NY (PRWEB) , ... August 21, 2017 , ... ... brands, was recently named one of the Top 100 agencies of the year by ... in MM&M’s annual agency issue, marking an important milestone for the agency. PIXACORE’s ...
(Date:8/20/2017)... ... 20, 2017 , ... A total solar eclipse will occur across the U.S. on ... moon moves between the sun and Earth. This rare event will be magnificent to witness, ... keep you safe on the road during the total eclipse of the sun. , 1. ...
(Date:8/19/2017)... ... August 18, 2017 , ... Western University of Health Sciences ... to launch the University’s new Center for Innovation on Wednesday, September 6, 2017. , ... Lecture Hall 1, followed by a technology exhibition from 1 to 3 p.m. showcasing ...
(Date:8/19/2017)... ... 19, 2017 , ... Praeclarus Press has launched a ... the diversity of the breastfeeding mothers, using bright colors and contemporary themes. ... illustrations are also available on tote bags, notepads, smartphone cases, clocks, and travel ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... CaryRx, a next-generation full-service pharmacy, has announced the ... in the Washington D.C. metropolitan area. ... delivery of medications through the convenience of its patient-friendly mobile ... within one hour to any location in D.C. ... invaluable service to Washington D.C. ," says ...
(Date:7/31/2017)... Surgical, developer of ground breaking surgical navigation technologies, announced today ... support its strategic sales plan in Maryland ... Surgical has entered into an exclusive sales representative agreement with ... those markets. ... Spartan Medical Purchases 7D Surgical Technology ...
(Date:7/27/2017)...  West Pharmaceutical Services, Inc. (NYSE: WST ... 2017 and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, ... Net sales at constant currency (organic) grew by 3.9%. ... compared to $0.60 in the prior-year quarter. Second-quarter 2017 ...
Breaking Medicine Technology: